Accurate detection and classification of somatic single nucleotide variants (SNVs) is important in defining the clonal composition of human cancers. Existing tools are prone to miss low prevalence mutations and methods for classification of mutations into clonal groups across the whole genome are underdeveloped. Increasing interest in deciphering clonal population dynamics over multiple samples in time or anatomic space from the same patient is resulting in whole genome sequence (WGS) data from phylogenetically related samples. With the access to this data, we posited that injecting clonal structure information into the inference of mutations from multiple samples would improve mutation detection.
Introduction

1
Genomic accumulation of somatic point mutations, or single nucleotide variants (SNVs) can disrupt the regular 2 activity of cells and may result in cancer initiation and progression. Collectively, the complete repertoire of SNVs 3 across a cancer genome (numbering in the thousands) form a statistically robust marker for inferring clonal 4 populations and studying tumour evolution. As such, accurate detection of all somatic SNVs, including those 5 with low prevalence, is vital as they can define clones with phenotypic properties of interest. Mechanistic 6 association of specific clones with properties such as treatment resistance, metastatic potential and fitness under 7 therapeutic selective pressures remains a key objective of biomedical investigators studying tumour progression. 8 Phylogenetic analysis can encode the evolutionary lineage of tumour cells across time and anatomic space 9 [7, 10, 14, 16, 17, 23, 25] . [6] sequenced multiple spatially separated samples from renal cell carcinomas and 10 related metastatic sites to reveal the evolutionary patterns. Samples were related through phylogenetic analysis 11 and distinguished at a coarse level mutations that were shared and ancestral from those that occurred in subsets 12 of cells. In a subsequent lung cancer study, 25 regions from seven non-small sections of malignant patients were 13 1/24 sequenced [2] and more recently the TRACERx study involving 100 lung cancer patients with 3 samples per 14 patient has reported genomic instability as a determinant of treatment response [10] . Our recent work has 15 determined clonal population dynamics over time in breast cancer xenografts [5] , follicular lymphoma timeseries 16 sampling across clinical trajectories [14] and anatomic space in intraperitoneal sites of primary high grade serous 17 ovarian cancer [16] , showing that the relative composition of constituent clones in multi-sample studies provides 18 major insight into disease spread.
19
In the limit case, all cells likely harbour unique genomes, however due to the nature of branched evolutionary 20 processes, clones can be coarsely modeled as major clades in the cell lineage phylogeny of a cancer. These clades 21 share the majority of mutations, and therefore define first approximations to the genotypes of clones. Clonal 22 genotypes and their relative abundances in the cancer cell population can be approximated by clustering 23 mutations measured in bulk tissues and estimating the cellular prevalences (the variant fraction of tumour cells) 24 [20, 26] . 25 Phylogenetic algorithms mostly use mutations (represented as binary genetic markers), as inputs to infer the 26 branched evolutionary lineages of tumour cells [3, 18] . Thus, accuracy of mutation detection will impact the 27 performance of phylogenetic inference algorithms.
28
Detection of low prevalence mutations is a major challenge due to weak signal to noise ratio, owing to: (i) 29 impure samples which are contaminated by normal cells, (ii) copy number alteration of the genome, and (iii) the 30 presence of mutations in only a fraction of tumour cells (intra-tumour heterogeneity). We assert in this work that 31 prior knowledge of clonal population structure will improve detection of mutations defining low prevalence clonal 32 genotypes.
33
Previous work
34
SNV calling algorithms are ubiquitous in the literature, but the problem remains challenging particularly for 35 detecting low prevalence mutations. Algorithms have been developed for calling mutations from a single sample 36 [8, 13] , paired (matched normal and tumour) samples [1, 4, 12, 19, 22] , or multiple samples [11, 24] . [4] uses a 37 feature based classifier called Mutationseq for calling mutations. The features are constructed from matched 38 paired normal and tumour samples. [22] introduced Strelka a method for somatic SNV and small indel detection 39 from sequencing data of matched normal and tumour samples. It is based on a Bayesian approach which uses 40 allele frequencies for both normal and tumour samples with the expected genotype structure of the normal. [1] 
41
proposed Mutect which uses a Bayesian classifier to detect mutations from matched normal and tumour samples. 42 It uses various filters to ensure high specificity. [11] proposed multiSNV which jointly considers all available 43 samples under a Bayesian framework to improve the performance of calling shared mutations. [21] and [24] refine 44 and correct the SNV calls from GATK [15] using the phylogeny information across multiple samples.
45
Our contribution
46
In MuClone, we exploit prior knowledge of tumour clone prevalence information and copy number inference 47 across multiple samples to improve the performance of detecting mutations, with the goal of better detecting low 48 prevalence clones. In this contribution, the clonal information is provided by running PyClone on the data 49 [16, 20] , and copy number information is estimated by TITAN [9] . However we note that the model can be 50 applied to clonal and copy number data obtained from any method. In addition, Muclone classifies mutations 51 into clusters sharing similar cellular prevalence which provides the opportunity of profiling their dynamic across 52 time or space and adds a rich layer of interpretation into the detection process.
53
We tested MuClone through simulation studies and an application to real, multiple sample, patient data.
54
These experiments reveal that incorporating the cellular prevalences of different clones improves accuracy.
55
Moreover, in real data MuClone exhibits higher sensitivity in detecting mutations without compromising 56 specificity compared with other methods. 
Notation
58
We begin by introducing notation used in the MuClone model. For each locus n = 1, . . . , N , the samples are 59 indexed from m = 1 . . . M .
60
We assume that bulk tumour DNA arises from three populations: (i) normal cells; (ii) malignant cells without 61 a mutation of interest (reference); and (iii) malignant cells with the mutation of interest (variant). The genotype 62 for locus n is denoted g n N , g n R , g n V , for normal, reference, and variant populations, respectively.
63
The symbol A denotes the allele that matches the reference genome; conversely, the symbol B denotes the Previously known clonal information from, for example, PyClone [16, 20] is encoded in an ordered list represents the cellular prevalence of the mth sample and zth clone. The K-vector τ represents prior the clonal 79 prevalence. In PyClone's case, the clonal prevalence of the zth clone is the empirical proportion of the number of 80 mutations in the zth clone to the total number of mutations clustered. Since our interest lies in calling mutations, 81 and many statistical models for inference of clonal population structure, including PyClone, only consider 82 somatic mutations, we extend Π to include a wildtype clone z = 0 and denote the resulting list as Π = (Φ, τ ). In 83 particular, we add a column of wildtype cellular prevalences to Φ to create Φ, and add a wildtype clone 84 prevalence to the vector τ ; τ is formed by normalizing (τ 0 , τ ).
85
MuClone
86
MuClone uses previously known cellular prevalence information to improve mutation detection and classification. 87 For each sample, MuClone detects mutations from joint analysis of multiple samples. We encode this process in a 88 generative probabilistic framework to perform joint statistical inference of multiple observations (from multiple 89 samples) of the variant allele counts of a mutation of interest.
90
The probabilistic graphical model of MuClone is depicted in Figure 1 . 
Model definition
92
For simplicity, we first assume that the number of reads containing the variant alleles at a given locus follows a Binomial distribution with genotype specific variant probability p(g) and read depth d
(
The variant probability p(g) :
where g is the genotype and > 0 is a small positive constant that accounts for sequencing error. It allows for 94 non-zero variant reads, due to sequencing error, when there are no variant alleles in genotype g.
95
3/24
However, since the sequenced reads are independently sampled from an infinite pool of DNA fragments, each 96 read may belong to the normal, reference, or variant population. Therefore, using a single genotype state, g,
97
introduces error into our analysis. To account for this fact, we consider using the full genotype state, ψ n m , at a 98 given locus n to model the number of variant reads.
99
The variant allele probability for the nth locus in the mth sample from the zth clone, denoted by 100 ξ(ψ n m , φ z m , t m ), is proportional to the sum of the (properly scaled) variant probabilities from each population:
where the first term
proportional to the probability of sampling a read containing variant 102 allele from the normal population, and the second and third terms,
103 are proportional to the probabilities of sampling a read containing variant alleles from the reference and variant 104 populations, respectively.
105
Considering the full genotype state, the number of reads containing the variant alleles at a given locus n that 106 belongs to clone Z n follows a Binomial distribution with probability
where accounts for sequencing error in wildtype clone and ξ(ψ 
110
Since empirical evidence shows that variant read data is overdispersed, we replace the Binomial model (1) with a BetaBinomial model
where p(Z n ) is the expected variant alleles probability and the hyperparameter s is the precision parameter of 111 the BetaBinomial distribution. The BetaBinomial distribution in Equation (5) assigns a small chance for 112 mutation when the locus is wildtype, otherwise it is governed by the prior clonal information.
113
To fully express our model, for each locus, we assume the genotype state follows a categorical distribution with probability vector π n m ∈ [0, 1]
|G| whose ith element is the probability of the ith genotype state
The number of possible genotype states, denoted by |G|, is finite given the copy number information. For 
115
In addition, we also assume that the clonal assignment of a locus, denoted by Z n , follows categorical distribution with probability vector τ :
Our probabilistic framework can be succinctly written as 
Inference
116
Based on the generative model introduced in (8) mutations are inferred via the posterior probability distribution of a locus n belonging to clone z,
where the variable i indexes π That is, if the probability η of belonging to any of the tumour clones is greater than 0.5, we conclude that the locus is mutated in at least one of the M samples. The value of η is
If locus n is mutated in at least one of the M samples, then the probability of mutation in each sample is calculated separately as
where J * m is the set of clones of sample m whose cellular prevalences are greater than a fixed positive threshold 121 called Φ T ,
The threshold Φ T distinguishes the clones of sample m in which their non-zero cellular prevalence are due to 123 actual variant alleles. The default value of Φ T is zero. However, depending on the method used for estimating 124 5/24 cellular prevalences, it can be set to another positive value, if some non-zero input cellular prevalences indicate 125 wildtype clones.
126
In addition, MuClone assigns the locus to clone z * that maximizes
This classifies mutations to one of the previously known clones. The classification of mutations helps in biological 127 interpretation and phylogenetic analysis of the data.
128
Experimental Result
129
We evaluated MuClone on both synthetic and real data. Synthetic data was generated for N number of loci, and M samples. We varied the number of tumour clones, K, 133 sequencing error rate, , and tumour content, t m , for each sample.
134
The cellular prevalences of tumour clones were sampled from a Uniform distribution over the closed interval 135 [0, 1] such that all clones are not present in all samples. Loci were randomly assigned to different clones. Then, 136 for each locus in each sample, the coverage was sampled from a Poisson distribution with the mean d m . Wildtype 137 copy number was deterministically set to 2 and a copy number profile (major and minor copy number) was 138 generated by the following steps: First, total copy number, C t , was sampled from integers between 1 and C max . 139 Second, an integer number, C b , was randomly picked from 1 to C t and C a was defined as C a = C t − C b . Last, 140 major copy number was set to the maximum of C b and C a ; minor copy number was set to the minimum of those 141 two values. Then, corresponding to each clone, the number of variant reads were sampled from the 142 Beta-Binomial distribution described in Equation (5). As expected, both sensitivity and specificity were highest when clonal information was most complete and 156 most accurate (Figure 2 ). This suggests that clonal information can indeed improve the accuracy of detecting 157 mutations and establishes the theory of MuClone's approach. Furthermore, sensitivity and specificity were only 158 marginally impacted by the added noise in the clonal information, suggesting MuClone should be able to cope 159 with the modest levels of erroneous information in the prior. 
170
The performance of MuClone was tested with various tumour content (from 0.1 to 0.99) and different error 171 rates (0.01 and 0.001) (Figure 4 ). For samples with tumour content greater than 0.5, sensitivity remained slightly 172 less than 1 and specificity near 1. Sensitivity and specificity dropped to only about 0.9 when the tumour content 173 in the sample was as low as 0.1, establishing promising performance over different ranges of tumour content with 174 different error rates (likely scenarios in real data).
175 Figure 5 demonstrates how well the mutations were classified by MuClone. The input clonal information had 176 been perturbed by adding noise with standard deviation of 0.01 to simulate a more realistic scenario. In 177 Figure 5 (a), each bin (i, j) shows the number of mutations belonging to clone i that MuClone classified them into 178 clone j, divided by the total number of mutations. Figure 5(a) shows 89% of mutations were classified into the 179 right clone as the diagonal elements are larger than the other ones.
180
In order to show that the classification errors have occurred between clones with small phylogenetic distance, we define misclassification index calculated as below:
, where q (i.j) is the number of mutations in clone i that have been classified into clone j. The Euclidean distance 181 between the cellular prevalences of clone i and j is dist (i,j) . The distance of the closest and farthest clone to 
Real data
186
We next tested MuClone's performance on whole genome sequencing data (30X) from multiple tumour samples 187 surgically resected from high grade serous ovarian cancer patients [16] . The samples were obtained from different 188 spatially distributed metastatic sites. Brief details about the number of samples for each patient, sample sites 189 and the number of validated loci for each patient are shown in Table S1 .
190
The clonal information and experimentally re-validated mutations status were taken from [16] , estimated from 191 running PyClone on the deep targeted sequencing data (>1000x coverage) from the same samples and in three 192 patients with accompanying single cell sequencing data (see Table S16 in [16] ). In order to eliminate germlines, 193 loci with any number of variant nucleotides in the corresponding normal sample were removed from the data set. 194 Then, the performance of MuClone was benchmarked against Strelka, MutationSeq, Mutect, MultiSNV and naive 195 MuClone. Naive MuClone is a version of MuClone where no clonal information is provided (which assumes that 196 all mutations are from the ancestral clone).
197
The performance of MuClone is compared with other methods in Figure 6 . The Youden's index, sensitivity and specificity was averaged across different samples of 7 patients. And each patient's performance is shown separately in Figures S3 to S9. Youden's index is calculated as:
Youden's index = Sensitivity + Specificity -1
In aggregate, MuClone outperforms other methods by improving sensitivity without compromising specificity 198 ( Figure 6 ). For each patient, the receiver operating characteristic (ROC) curves are shown in Figures S10 to S16 . 199 The detailed number of miscalled loci are listed in Table S2 . False negatives are mainly because the WGS data is 200 under-represented (the average depth of the WGS data is about 30X) and lacks any variant alleles that are 201 present in the targeted sequencing data. The false positives are mostly because of technical artefacts.
202
In Figure 6 , Strelka, MutationSeq, Mutect and Naive MuClone have lower performance as they do not was statistically higher than MultiSNV (p-value = 0.0006). Importantly, MuClone improves sensitivity, enabling 206 the detection of more mutations across whole genome. Figure 7 depicts the classification of mutations into clones 207 relative to ground truth, as defined by running PyClone on the data (omitting singleton clusters [16] ). Each bin 208 shows the normalized number of mutations. 93% of the elements in Figure 7 are diagonal which means MuClone 209 classifies them correctly. Misclassification index for patient 1 is 0.015 which implies that misclassified mutations 210 are classified into phylogenetically close clones.
4 Discussion and Conclusion
212
We studied the use of clonal information for the purpose of somatic mutation detection and classification in results suggest improvement in sensitivity can be achieved without compromising specificity. As accuracy of 219 detecting mutations can affect the performance of phylogenetic analysis, we suggest this improvement will impact 220 the field of multi-region sequencing for cancer evolution studies. As the field matures, we expect the method 221 presented here will be incorporated into more analytically comprehensive modelling of whole genome sequencing 222 data when multiple samples are used to infer properties of clonal dynamics. We suggest the next steps are a Figure S16. MuClone's Roc curves and the area under the curve (AUC) for patient 10. MuClone's parameters: Wildtype prior is 0.5, Φ T is 0.02, error rate is 0.01, and precision parameter equals 1000.
